We appreciate Chen et al.'s [1] comments on our review on systemic treatment options for hepatocellular carcinoma (HCC) [2]. Chen and colleagues discuss three important aspects. First, the lack of predictive biomarkers for currently used targeted agents, which is a limitation for patient selection, and the need to identify such biomarkers. Chen et al. specifically mention MET as a potential predictive biomarker, but two phase 3 trials testing tivantinib (a MET inhibitor) and selecting patients according to MET expression failed to meet their primary endpoints [3, 4]. The only positive phase 3 trial in a biomarker-selected population with HCC is the REACH-2 trial of ramucirumab in patients with high baseline alpha-fetoprotein levels [5]. Although we fully agree with Chen et al. that the lack of predictive biomarkers in HCC represents a highly unmet clinical need, at present we should base our clinical decisions on the data we have, and specifically on the results of clinical trials and on patient clinical characteristics. Further data on predictive biomarkers are certainly warranted.
